Surgimab
  • Science
    • Technology
    • Pipeline
    • Clinical trials
    • Publications
  • About SurgiMab
    • History
    • Our team
    • Partners
  • News
  • Contact
Select Page
SurgiMab will attend the World Molecular Imaging Congress 2016 in New York, september 7-10.

SurgiMab will attend the World Molecular Imaging Congress 2016 in New York, september 7-10.

by kwal1 | Jul 19, 2016 | News

SurgiMab will attend WMIC 2016 : Bérénice Framery, in charge of the company’s internal R&D programs, will be present in New York. You can meet her in particular during the “Optical Surgical Navigation” session on Wednesday, September 7, 2016,...
SurgiMab will participate to the BIO International convention 6-9 June 2016

SurgiMab will participate to the BIO International convention 6-9 June 2016

by kwal1 | May 12, 2016 | News

Let’s meet at the Moscone Center in San Francisco, June 6-9 for the BIO International convention! The company presentation will take place in Room 4 on Wednesday the 8th, 5:00 PM during the Oncology session. Françoise Cailler, CEO of the company, will update the...
February 13-14th, San Francisco. SurgiMab is happy to be a sponsor of the conference “Molecular-Guided Surgery: Molecules, Devices and Applications II” organised during the SPIE Photonics West congress.

February 13-14th, San Francisco. SurgiMab is happy to be a sponsor of the conference “Molecular-Guided Surgery: Molecules, Devices and Applications II” organised during the SPIE Photonics West congress.

by kwal1 | Feb 13, 2016 | News

SurgiMab is happy to be part of the sponsors for the conference “Molecular Guided Surgery : Molecules, Devices and Applications II”, organized par Brian W. Pogue and Sylvain Gioux as a part of the SPIE photonics West meeting that will take place at the...
SurgiMab launches clinical trial in patients with pancreatic or rectal cancer

SurgiMab launches clinical trial in patients with pancreatic or rectal cancer

by kwal1 | Feb 5, 2016 | News

Montpellier, France, February 5th, 2016. SurgiMab announces the launch of a phase I clinical trial program evaluating the safety and performance of its fluorescent conjugate SGM-101 in patients with pancreatic or rectal cancer. SurgiMab, founded in 2011 in...

Hawaï. SurgiMab is happy to be a sponsor for the one-day Optical Surgical Navigation Seminar organised during WMIC.

by kwal1 | Sep 2, 2015 | News

SurgiMab is happy to be part of the sponsors for the one-day Optical Surgical Navigation Seminar that is organized on september the 2nd during the World Molecular Imaging Congress in Hawaï. SurgiMab will also present its latest results on September 3rd during the WMIC...

First-in-human phase I study for SurgiMab’s molecule SGM-101 launched in Montpellier Cancer Institute

by kwal1 | May 15, 2015 | News

SurgiMab, a French company founded in 2011 in Montpellier, is developing antibody-fluorochrome conjugates as in vivo diagnostic agents in oncology. “Today we are pleased to announce that Montpellier Cancer Institute (ICM) has started patient inclusion in a phase I...
« Older Entries
Next Entries »

Articles récents

  • SurgiMab Honored with the “Tech for Future 2025” Award in Healthcare by La Tribune, France – April 2, 2025
  • Françoise Cailler, CEO of surgiMab, will attend the WMIC2024 Congress in Montreal
  • SurgiMab will sponsor the next edition of the International Symposium on Fluorescence Guided Surgery, 2-3 Nov 2023 in Amsterdam
  • SurgiMab will participate to the conference “Optics in the Life Sciences” during the Optica Biophotonics Congress in Vancouver April 23 – 27, 2023
  • SurgiMab co-sponsors the Molecular-Guided Surgery meeting that will take place during the SPIE Photonics West conference in San Francisco on Jan 22-23, 2022.

Commentaires récents

No comments to show.

Contact

Francoise Cailler: +33 467 798 381
Michel Barbelanne: +33 467 798 382

Legal

Legals, privacy & cookies

  • Science
    • Technology
    • Pipeline
    • Clinical trials
    • Publications
  • About SurgiMab
    • History
    • Our team
    • Partners
  • News
  • Contact